← Back to Screener
Rigel Pharmaceuticals Inc. (New) (RIGL)
Price$31.77
Favorite Metrics
Price vs S&P 500 (26W)7.49%
Price vs S&P 500 (4W)20.20%
Market Capitalization$581.63M
P/E Ratio (Annual)1.58x
All Metrics
P/CF (Annual)7.69x
Book Value / Share (Quarterly)$21.38
P/TBV (Annual)2.12x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)34.78%
Cash Flow / Share (Quarterly)$4.13
Price vs S&P 500 (YTD)-27.79%
Gross Margin (TTM)93.33%
Net Profit Margin (TTM)124.72%
EPS (TTM)$18.62
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$18.62
Revenue Growth (5Y)22.06%
EPS (Annual)$19.48
ROI (Annual)82.71%
Gross Margin (Annual)93.33%
Net Profit Margin (5Y Avg)10.45%
Cash / Share (Quarterly)$8.46
P/E Basic Excl Extra (TTM)1.58x
Revenue Growth QoQ (YoY)21.19%
P/E Normalized (Annual)1.58x
ROA (Last FY)71.46%
Revenue Growth TTM (YoY)67.45%
EBITD / Share (TTM)$6.76
ROE (5Y Avg)70.99%
Operating Margin (TTM)42.63%
Cash Flow / Share (Annual)$4.13
P/B Ratio1.49x
P/B Ratio (Quarterly)1.99x
Net Income / Employee (Annual)$2
EV / Revenue (TTM)2.02x
Net Interest Coverage (TTM)34.48x
ROA (TTM)128.91%
EPS Growth QoQ (YoY)1559.22%
EV / EBITDA (TTM)4.64x
EPS Incl Extra (Annual)$19.48
Current Ratio (Annual)2.42x
Quick Ratio (Quarterly)2.08x
3-Month Avg Trading Volume0.42M
52-Week Price Return86.29%
EV / Free Cash Flow (Annual)7.84x
P/E Incl Extra (TTM)1.58x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$20.03
P/S Ratio (Annual)1.98x
Asset Turnover (Annual)0.57x
52-Week High$52.24
Operating Margin (5Y Avg)-3.21%
EPS Excl Extra (Annual)$19.48
CapEx CAGR (5Y)-22.97%
26-Week Price Return11.47%
Quick Ratio (Annual)2.08x
13-Week Price Return-19.77%
Total Debt / Equity (Annual)0.13x
Current Ratio (Quarterly)2.42x
Enterprise Value$593.341
Revenue / Share Growth (5Y)89.25%
Asset Turnover (TTM)1.03x
Book Value / Share Growth (5Y)100.65%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)2.24x
Pretax Margin (Annual)41.40%
Cash / Share (Annual)$8.46
3-Month Return Std Dev46.88%
Gross Margin (5Y Avg)94.95%
Net Income / Employee (TTM)$2
ROE (Last FY)93.75%
Net Interest Coverage (Annual)34.48x
EPS Basic Excl Extra (Annual)$19.48
P/FCF (TTM)7.60x
Receivables Turnover (TTM)6.30x
EV / Free Cash Flow (TTM)7.84x
Total Debt / Equity (Quarterly)0.13x
EPS Incl Extra (TTM)$18.62
Receivables Turnover (Annual)6.30x
ROI (TTM)174.53%
P/S Ratio (TTM)1.98x
Pretax Margin (5Y Avg)-6.04%
Revenue / Share (Annual)$15.62
Tangible BV / Share (Annual)$20.03
Forward P/E7.31x
Price vs S&P 500 (52W)56.46%
P/E Ratio (TTM)1.58x
EPS Growth TTM (YoY)1813.52%
Year-to-Date Return-25.15%
5-Day Price Return5.08%
EPS Normalized (Annual)$19.48
ROA (5Y Avg)1.28%
Net Profit Margin (Annual)124.72%
Month-to-Date Return18.57%
Cash Flow / Share (TTM)$-0.14
EBITD / Share (Annual)$6.79
Operating Margin (Annual)42.63%
LT Debt / Equity (Annual)0.06x
P/CF (TTM)7.69x
ROI (5Y Avg)-17.10%
P/E Excl Extra (TTM)1.58x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$18.62
P/TBV (Quarterly)2.12x
P/B Ratio (Annual)1.99x
Inventory Turnover (TTM)2.24x
Pretax Margin (TTM)41.40%
Book Value / Share (Annual)$21.38
Price vs S&P 500 (13W)-20.46%
Beta1.33x
P/FCF (Annual)7.69x
Revenue / Share (TTM)$14.55
ROE (TTM)240.83%
52-Week Low$16.05
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RIGLRigel Pharmaceuticals Inc. (New) | 1.98x | 67.45% | 93.33% | — | $31.77 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Rigel Pharmaceuticals develops small-molecule therapeutics for autoimmune, cancer, and viral diseases. The company markets TAVALISSE, an oral SYK inhibitor, and generates revenue through a partnership with AstraZeneca for an oral rheumatoid arthritis candidate, earning royalties and milestone payments. Its pipeline includes additional candidates targeting SYK and JAK pathways.